| Identification | Back Directory | [Name]
3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE | [CAS]
202821-81-6 | [Synonyms]
BMS-A
BMS 191011
-5-(4-(trifluoromethyl)
BMS-191011 >=98% (HPLC)
3-(5-Chloro-2-hydroxybenzyl)
3-(5-chloro-2-hydroxybenzyl)-5-(4-(trifluoroMethyl)phenyl)-1,3,4
3-(5-chloro-2-hydroxybenzyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one
3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE
1,3,4-Oxadiazol-2(3H)-one, 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]- | [Molecular Formula]
C16H10ClF3N2O3 | [MDL Number]
MFCD09753285 | [MOL File]
202821-81-6.mol | [Molecular Weight]
370.71 |
| Chemical Properties | Back Directory | [Boiling point ]
444.0±55.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: soluble20mg/mL, clear (warmed) | [form ]
powder | [pka]
9.27±0.43(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Description]
BMS 191011 is an activator of large-conductance calcium-activated potassium (KCa1.1/BK) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human KCa1.1 channels when used at a concentration of 1 μM. In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the KCa1.1 channel blocker iberiotoxin . | [Uses]
BMS 191011, is a potent opener of the large-conductance, Ca2+-activated potassium (maxi-K) channel. It has also shown neuroprotective properties in two distinct animal models of stroke- MCAO in the SHR rat and a normotensive model of focal stroke. | [Definition]
ChEBI:3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one is a member of (trifluoromethyl)benzenes. | [Biological Activity]
Potent Maxi-K channel opener (large-conductance Ca 2+ -activated potassium channel, K Ca 1.1, BK Ca ). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). | [storage]
Store at RT | [References]
[1]. hewawasam p, ding m, chen n, et al. synthesis of water-soluble prodrugs of bms-191011: a maxi-k channel opener targeted for post-stroke neuroprotection. bioorganic & medicinal chemistry letters, 2003, 13(10): 1695-1698.
[2]. valverde ma, rojas p, amigo j, et al. acute activation of maxi-k channels (hslo) by estradiol binding to the β subunit. science, 1999, 285(5435): 1929-1931.
[3]. zhang y, bonnan a, bony g, et al. dendritic channelopathies contribute to neocortical and sensory hyperexcitability in fmr1-/y mice. nature neuroscience, 2014, 17(12): 1701-1709.
[4]. gu xq, pamenter me, siemen d, et al. mitochondrial but not plasmalemmal bk channels are hypoxia-sensitive in human glioma. glia, 2014, 62(4): 504-513.
[5]. mori a, suzuki s, sakamoto k, et al. bms-191011, an opener of large-conductance ca2+-activated potassium channels, dilates rat retinal arterioles in vivo. biological and pharmaceutical bulletin, 2011, 34(1): 150-152.
[6]. romine jl, martin sw, meanwell na, et al. 3-[(5-chloro-2-hydroxyphenyl) methyl]-5-[4-(trifluoromethyl) phenyl]-1, 3, 4-oxadiazol-2 (3 h)-one, bms-191011: opener of large-conductance ca2+-activated potassium (maxi-k) channels, identification, solubility, and sar. journal of medicinal chemistry, 2007, 50(3): 528-542. |
|
| Company Name: |
Jia Xing Isenchem Co.,Ltd
|
| Tel: |
0573-85285100 18627885956 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList14265/0.htm |
|